Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/CCM.0000000000001051 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effective Bone Tissue Fabrication Using 3D-Printed Citrate-Based Nanocomposite Scaffolds Laden with BMP9-Stimulated Human Urine Stem Cells.
ACS Appl Mater Interfaces
January 2025
Molecular Oncology Laboratory, Department of Orthopedic Surgery and Rehabilitation Medicine, The University of Chicago Medical Center; Chicago, Illinois 60637, United States.
Effective repair of large bone defects through bone tissue engineering (BTE) remains an unmet clinical challenge. Successful BTE requires optimal and synergistic interactions among biocompatible scaffolds, osteogenic factors, and osteoprogenitors to form a highly vascularized microenvironment for bone regeneration and osseointegration. We sought to develop a highly effective BTE system by using 3D printed citrate-based mPOC/hydroxyapatite (HA) composites laden with BMP9-stimulated human urine stem cells (USCs).
View Article and Find Full Text PDFDevelopment of citric acid-based biomaterials for biomedical applications.
J Mater Chem B
November 2024
Engineering Research Center for Biomedical Materials of Ministry of Education, Frontiers Science Center for Materiobiology and Dynamic Chemistry, School of Material Science & Engineering, East China University of Science and Technology, Shanghai 200237, China.
Article Synopsis
- - The study focuses on citric acid-based biomaterials, emphasizing their advantages like easy synthesis, adjustable properties, and compatibility with biological systems.
- - It reviews the multifunctional aspects of these biomaterials, considering their physical, chemical, and biological properties.
- - The paper highlights various applications of citrate-based biomaterials in biomedical engineering, including uses in bone and skin tissue engineering, drug delivery, and bioimaging.
Optimizing Continuous Renal Replacement Therapy with Regional Citrate Anticoagulation: Insights from the ORCA Trial-A Retrospective Study on 10 Years of Practice.
Life (Basel)
October 2024
The Departments of Critical Care Medicine, Antwerp University Hospital, 2650 Edegem, Belgium.
(1) Background: Citrate is preferred in continuous renal replacement therapy (CRRT) for critically ill patients because it prolongs filter life and reduces bleeding risks compared to unfractionated heparin (UFH). However, regional citrate anticoagulation (RCA) can lead to acid-base disturbances, citrate accumulation, and overload. This study compares the safety and efficacy of citrate-based CRRT with UFH and no anticoagulation (NA) in acute kidney injury (AKI) patients.
View Article and Find Full Text PDFComparative Effects of Acetate- and Citrate-Based Dialysates on Dialysis Dose and Protein-Bound Uremic Toxins in Hemodiafiltration Patients: Exploring the Impact of Calcium and Magnesium Concentrations.
Toxins (Basel)
October 2024
Nephrology and Renal Transplantation, Hospital Clínic de Barcelona, 08036 Barcelona, Spain.
Article Synopsis
- Modern hemodialysis typically uses acetate as a buffer, which has been associated with chronic inflammation, while citrate is being explored as a potential alternative for dialysate.
- This study compares the efficacy of acetate- and citrate-based dialysates in terms of dialysis efficiency and the removal of protein-bound uremic toxins in patients undergoing hemodiafiltration.
- Results showed no significant differences in overall dialysis doses or most toxin reduction, but lower calcium and magnesium citrate dialysates led to better clearance of p-cresyl sulfate, indicating a need for further research to optimize dialysate formulas.
Switching from acetate to citrate dialysate in a central concentrate delivery system for high-volume online hemodiafiltration: a retrospective cohort study.
Ren Fail
December 2024
Division of Nephrology, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Republic of Korea.
Article Synopsis
- Interest in citrate-based dialysate (Cit-D) is increasing due to its advantages in anticoagulation and dialysis efficiency, yet research on its use in high-volume hemodiafiltration (HDF) is limited.
- This study analyzed 28 patients who switched from acetate-based dialysate (Acet-D) to Cit-D, examining safety and effectiveness across three 12-week periods.
- Results showed a 17% reduction in heparin dosage, improvements in dialysis efficiency (increased Kt/V and urea reduction ratio), and no significant safety concerns, suggesting Cit-D may have benefits over Acet-D in this setting.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!